4B.08: SERUM LEVELS OF TIMP-1 AND IL-6 ARE ASSOCIATED WITH HYPERTENSION AND ATHEROSCLEROSIS IN PATIENTS WITH EARLY STAGES OF CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETIC NEPHROPATHY. (June 2015)

• Record Type: Journal Article
• Authors: Dimas, G.; Iliadis, F.; Tegos, T.; Spiroglou, S.; Kanellos, I.; Karamouzis, I.; Savopoulos, C.; Hatzitolios, A.; Grekas, D.
• Is Part Of: Journal of hypertension. Volume 33(2015)Supplement 1
• Publication Date: 2015-06
• Subjects: Hypertension -- Periodicals; Hypertension -- Periodicals; 616.132005
• DOI: 10.1097/01.hjh.0000467492.91729.d5
• Languages: English
• ISSNs: 1473-5598

Abstract

Abstract : Objective: Tissue inhibitor of metalloproteinase -1 (TIMP-1) has been identified in humans and its expression is regulated during development and tissue remodeling. TIMP-1 overexpression in a mouse model of atherosclerosis showed a lesion reduction. Interleukine-6 (IL-6) is considered to be pro-inflammatory lipocytokine. The aim of the present study was to determine the serum levels of TIMP-1 and IL-6 and to investigate their potential correlation with hypertension, atherosclerotic markers and albuminuria in early stages of type 2 diabetic nephropathy (DN). Design and method: CKD patients of stages 1 and 2 with type II DN (n = 50) were included. As controls, there were two groups, patients with diabetes type II without CKD (n = 40) and healthy individuals (n = 40). Clearance of creatinine (Clcr) and albumin excretion were examined in the 24 h urine. TIMP-1 and IL-6 levels were measured by an ELISA method. Blood pressure (BP) was taken using a manual sphygmomanometer. Intima media thickness (IMT) of carotid and femoral arteries and atheromatic plaque were evaluated by a high resolution ultrasonography. Statistical analysis was performed with the use of a SPSS system. Results: There was a statistically significant difference between TIMP-1 (400 ± 20, p < 0.0001), IL-6 (4 ± 0.5, p < 0.0001), BP (20 ± 5, p < 0.0001) and IMT (0.3 ± 0.09, p < 0.0001) between patients and controls. There was a statistically significant negative strong correlation between levels of TIMP-1 and IL-6 (r = −0.7, p < 0.0001), such as between TIMP-1 and IMT (r = −0.65, p < 0.0001) in the patient group. There was also a statistically positive correlation between IL-6 and IMT (r = 0.7, p < 0.0001) in the patient group. Further, TIMP-1 and IL-6 levels were independently correlated with IMT and atheromatic plaque. Conclusions: Our study suggests that serum levels of TIMP-1 and IL-6 might present independent risk factors of blood pressure, atherosclerosis and albuminuria, at least in the early stages of type II diabetic nephropathy to the progression of CKD.